Revised model factoring in PCM-075 (AML drug) as the key driver of the company going forward - sets $4 target price.

Maxim Group upgrades Trovagene from a "hold" position to a "buy" position based on PCM-075 (AML drug candidate) as the key driver of the company going forward

Announces restructuring program to support its expansion into precision cancer therapeutics

Authors conclude that ctDNA testing demonstrates clinical utility in assessing disease burden and response to therapy

Performance of Trovera™ ctDNA KRAS in blood and urine has similar concordance to standard of care tissue molecular diagnostics

Seven new partners to commercialize Trovera™ liquid biopsy tests in Europe and the Middle East

Companies to develop and commercialize multiplexed urine and blood ctDNA liquid biopsy assay kits for global distribution

Trovera™ liquid biopsy test selected by the Pancreatic Cancer Action Network for its industry-leading sensitivity and ability to rapidly and quantitatively assess response to therapy

BCBS Illinois expands patient access to Trovera™ tests for 8.1 million covered lives

Author concludes that confirmation of EGFR mutational status using urine ctDNA analysis should be considered in treatment decision-making

Data confirms EGFR Activating Mutations and EGFR T790M in metastatic non-small cell lung cancer (NSCLC) diagnosis in urine and blood with high sensitivity and specificity

Trovagene's KRAS ctDNA liquid biopsy test will be at the forefront of research partnership with Dr. Diane Simeone at University of Michigan Health System

Results validate urine ctDNA testing as an alternative to tissue and plasma based on a large prospective study of T790M detection and patient response to an EGFR tyrosine kinase inhibitor

Results from 213 patient study demonstrates use of urinary ctDNA as a stand-alone test for the highly sensitive detection of EGFR T790M mutations for therapy selection

92.9% of metastatic pancreatic cancer patients determined to be KRAS positive using Trovagene's Precision Cancer Monitoring assay

Confirmation of BRAF V600E mutational status and quantitative monitoring of changes in urinary ctDNA used to assess response to novel combination drug therapy for colorectal neuroendocrine tumors

Urinary liquid biopsy shown to monitor early drug response to anti-EGFR therapy

High clinical sensitivity and longitudinal monitoring of KRAS mutations across multiple cancer types demonstrated in urine

Ultra-high sensitivity drives clinical applications and pharmacodynamic monitoring in late-stage cancer patients

Agreement expands in-network health benefit access to Trovagene's Precision Cancer Monitoring platform for an additional 68 million covered lives